medigraphic.com

2018, Número 5

<< Anterior Siguiente >>

Rev Clin Esc Med 2018; 8 (5)


Cardiotoxicidad de los Quimioterapéuticos Diferentes a Antraciclinas de la Lista Oficial de Medicamentos de la Caja Costarricense del Seguro Social

Salas SJ, Pérez CJI

Idioma: Español
Referencias bibliográficas: 41
Paginas: 1-10
Archivo PDF: 681.17 Kb.


RESUMEN

La Cardio-oncología es una nueva disciplina que busca enfocarse en el tamizaje, monitoreo y tratamiento de los pacientes con cáncer que presentan enfermedad cardiaca durante o después de recibir tratamiento. Esto debido a que el efecto cardiotóxico asociado a los quimioterapéuticos es ampliamente conocido y respaldado por abundantes estudios clínicos. Sin embargo, no es hasta épocas recientes que en Costa Rica se desarrollaron por primera vez Unidades Cardio-oncológicas, los cuales actualmente se ubican en diversos centros médicos de nuestro sistema de salud público. A continuación, se presenta un resumen de las manifestaciones clínicas de las diversas terapias oncológicas diferentes a las antraciclinas que tenemos a disposición en la Caja Costarricense del Seguro Social (CCSS).


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Adão R De Keulenaer G Leite-Moreira A Brás-Silva C. Cardiotoxicity associated with cancer therapy: Pathophysiology and prevention. Rev Port Cardiol. 2013; 32(5): 395-409.

  2. 2.Lenneman C Sawyer D. Cardio-Oncology: An Update on Cardiotoxicity of Cancer-Related Treatment. Circ Res. 2016; 118:1008-1020.

  3. 3.LópezFernández T Thavendiranathan P. Nuevas técnicas de imagen cardiaca en la detección precoz de cardiotoxicidad secundaria a tratamientos oncológicos. Rev Esp Cardiol. 2017; 70(6): 487-495.

  4. Plana JC Galderisi M Barac A et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014 Sep;27(9):911-39.

  5. Tajiri K Aonuma K Sekine I. Cardio-oncology: a multidisciplinary approach for detection, prevention and management of cardiac dysfunction in cancer patients. Jpn J Clin Oncol. 2017; 47(8): 678-682.

  6. Plana JC Galderisi M Barac A et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014; 27(9):911-39.

  7. Gottdiener JS Appelbaum FR Ferrans VJ Deisseroth A Ziegler J. Cardiotoxicity associated with highdose cyclophosphamide therapy. Arch Intern Med. 1981;141(6):758.

  8. Appelbaum F Strauchen JA Graw RG Jr et al. Acute lethal carditis caused by high-dose combination chemotherapy. A unique clinical and pathological entity. Lancet. 1976;1(7950):58.

  9. Quezado ZM Wilson WH Cunnion RE et al. Highdose ifosfamide is associated with severe, reversible cardiac dysfunction. Ann Intern Med. 1993; 118(1):31.

  10. 10.Kandylis K Vassilomanolakis M Tsoussis S Efremidis AP. Ifosfamide cardiotoxicity in humans. Cancer Chemother Pharmacol. 1989; 24(6):395.

  11. 11.Huddart RA Norman A Shahidi M et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol. 2003;21(8):1513.

  12. 12.Fung C Sesso HD Williams AM et al. Multi- Institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-Based Chemotherapy. J Clin Oncol. 2017; 35(11):1211.

  13. 13.Perry MC. Effects of chemotherapy on the heart. In: Cancer and the Heart. Kapoor AS (Ed), Springer Verlag, New York. 1986; p.223.

  14. 14.Grem JL. 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development. Invest New Drugs. 2000; 18(4):299-313.

  15. 15.Saif MW Shah MM Shah AR. Fluoropyrimidineassociated cardiotoxicity: revisited. Expert Opin Drug Saf. 2009; 8(2):191.

  16. 16.Jensen SA Hasbak P Mortensen J Sørensen JB. Fluorouracil induces myocardial ischemia with increases of plasma brain natriuretic peptide and lactic acid but without dysfunction of left ventricle. J Clin Oncol. 2010; 28(36):5280.

  17. 17.Kosmas C Kallistratos MS Kopterides P et al. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol. 2008; 134(1):75-82.

  18. 18.Yoshida T Araki E Ligo M et al. Clinical significance of monitoring serum levels of 5-fluorouracil by continuous infusion in patients with advanced colonic cancer. Cancer Chemother Pharmacol. 1990; 26(5):352-4.

  19. de Forni M Malet-Martino MC Jaillais P et al. Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. J Clin Oncol. 1992;10(11):1795.

  20. 20.Kettunen R Huikuri HV Oikarinen A Takkunen JT. Methotrexate-linked ventricular arrhythmias. Acta Derm Venereol. 1995;75(5):391.

  21. 21.Perez-Verdia A Angulo F Hardwicke FL Nugent KM. Acute cardiac toxicity associated with highdose intravenous methotrexate therapy: case report and review of the literature. Pharmacotherapy. 2005;25(9):1271.

  22. 22.Hermans C Straetmans N Michaux JL Ferrant A. Pericarditis induced by high-dose cytosine arabinoside chemotherapy. Ann Hematol. 1997; 75(1-2):55.

  23. 23.Keefe DL. Trastuzumab-associated cardiotoxicity. Cancer. 2002; 95(7):1592.

  24. 24.Russell SD Blackwell KL Lawrence J et al. Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials. J Clin Oncol. 2010;28(21):3416.

  25. 25.Millward PM Bandarenko N Chang PP et al. Cardiogenic shock complicates successful treatment of refractory thrombotic thrombocytopenia purpura with rituximab. Transfusion. 2005; 45(9):1481.

  26. 26.Cersosimo RJ. Monoclonal antibodies in the treatment of cancer, Part 1. Am J Health Syst Pharm. 2003;60(15):1531.

  27. 27.Cargill RI Boyter AC Lipworth BJ. Reversible myocardial ischaemia following vincristine containing chemotherapy. Respir Med. 1994; 88(9):709.

  28. 28.Yancey RS Talpaz M. Vindesine-associated angina and ECG changes. Cancer Treat Rep. 1982;66(3):587.

  29. 29.Gehl J, Boesgaard M Paaske T Vittrup Jensen B Dombernowsky P. Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic. Ann Oncol. 1996;7(7):687.

  30. 30.Malhotra V Dorr VJ Lyss AP et al. Neoadjuvant and adjuvant chemotherapy with doxorubicin and docetaxel in locally advanced breast cancer. Clin Breast Cancer. 2004; 5(5):377.

  31. 31.Fossella FV Lee JS Murphy WK et al. Phase II study of docetaxel for recurrent or metastatic nonsmall- cell lung cancer. J Clin Oncol. 1994;12(6):1238. 32.Verweij J Funke-Küpper AJ Teule GJ, Pinedo HM. A prospective study on the dose dependency of cardiotoxicity induced by mitomycin C. Med Oncol Tumor Pharmacother. 1988;5(3):159.

  32. 33.Ravry MJ. Cardiotoxicity of mitomycin C in man and animals. Cancer Treat Rep. 1979;63(4):555.

  33. 34.White DA Schwartzberg LS Kris MG Bosl GJ. Acute chest pain syndrome during bleomycin infusions. Cancer. 1987;59(9):1582.

  34. 35.Vogelzang NJ Frenning DH Kennedy BJ. Coronary artery disease after treatment with bleomycin and vinblastine. Cancer Treat Rep. 1980;64(10-11):1159.

  35. 36.Schecter JP Jones SE Jackson RA. Myocardial infarction in a 27-year-old woman: possible complication of treatment with VP-16-213 (NSC- 141540), mediastinal irradiation, or both. Cancer Chemother Rep. 1975;59(5):887.

  36. 37.Yano S Shimada K. Vasospastic angina after chemotherapy with carboplatin and etoposide in a patient with lung cancer. Jpn Circ J. 1996;60(3):185.

  37. 38.Kerkelä R Grazette L Yacobi R et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med. 2006;12(8):908.

  38. 39.Atallah E Durand JB Kantarjian H Cortes J. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood. 2007;110(4):1233.

  39. 40.Hunt SA Abraham WT Chin MH et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119(14):391.

  40. 41.National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology. Disponible en: www.nccn.org/ professionals/physician_gls/f_guidelines.asp. Accesado en Marzo 2018.

  41. 42.Caja Costarricense de Seguro Social. Lista oficial de medicamentos. 2013. Disponible en www.ccss. sa.cr/lom. Accesado en Marzo del 2018.




2020     |     www.medigraphic.com